Undetectable MRD and Extended PFS More Common with MRD-guided Ibrutinib-Venetoclax than with Ibrutinib Alone or FCR Regimen Among Patients with CLL By Ogkologos - October 13, 2025 345 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the FLAIR study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Announces 2026 Society Award Recipients Honouring Excellence in Cancer Research, Care and Leadership Adjuvant Olaparib Continues to Improve Multiple Outcomes in Patients with Germline BRCA1/2-associated High-Risk HER2-negative EBC EMA Recommends Refusing the Marketing Authorisation for Copper (64Cu) Oxodotreotide MOST POPULAR Researchers Develop a Potential “Universal” CAR T-Cell Therapy for Blood Cancers September 27, 2023 Modest Population-Level Increases in Survival Observed After Implementation of Immune Checkpoint... February 1, 2023 Should People With Cancer Be Tested for Hepatitis B? July 27, 2020 What to Know About Kidney Cancer Genetic Conditions and Genetic Counseling June 9, 2021 Load more HOT NEWS Mom Warns Others After Little Girl’s Skin Blisters From ‘Margarita Burn’ DeFi Trial: Smart Design and Impressive Results For the Benefit of... Does Living Near Power Lines Increase My Risk of Cancer? Pembrolizumab May Help Prevent Early-Stage Melanoma from Returning
